Caredx, INC

CareDx reported a 52% year-over-year revenue increase to $132 million for Q2 2026, driven by strong Testing Services growth, and raised its full-year revenue and AEBITDA guidance.

CareDx, Inc. has finalized the sale of its Lab Products business to Eurobio Scientific for $171.7 million and acquired Naveris, Inc. for an initial $161.8 million, expanding its presence in specialty oncology.

CareDx's 2026 Annual Meeting saw stockholders approve an amendment to the 2024 Equity Incentive Plan, increasing available shares by 1.6 million.

CareDx, Inc. announced its definitive agreement to acquire Naveris, Inc. for $160 million in cash, with potential for an additional $100 million in milestone-based payments, expanding its precision medicine offerings into oncology.

CareDx, Inc. amends its prior 8-K filing to detail compensation adjustments for its newly appointed Chief Financial Officer, Keith Kennedy.

CareDx has entered into a definitive agreement to sell its Lab Products business to Eurobio Scientific for $170 million in cash to focus on core precision medicine testing.

CareDx, Inc. announced robust financial results for the second quarter of 2026, with total revenue reaching $131.9 million and net income soaring to $110.6 million.

CareDx, Inc. announced a significant 39% year-over-year increase in total revenue for the first quarter of 2026, reaching $118 million, driven primarily by a 48% surge in testing services revenue.

CareDx, Inc. announced a return to net income in Q3 2025 with significant revenue growth across its testing services, products, and digital solutions, despite ongoing legal challenges and an unaddressed material weakness in internal controls.

CareDx reports a 6% revenue decline to $86.7 million in Q2 2025, driven by prior period adjustments, but sees growth in product and digital solutions, alongside significant legal developments.

CareDx, a precision medicine company focused on transplant solutions, announced an 18% year-over-year increase in revenue for the first quarter of 2025, reaching $84.7 million, while navigating legal challenges and internal control weaknesses.

CareDx, a precision medicine company, announced a 23% year-over-year revenue increase in the third quarter of 2024, driven by growth in testing services, while navigating legal proceedings and a changing regulatory landscape.

CareDx, a precision medicine company, reported a 14% increase in total revenue to $379.8 million for fiscal year 2025, alongside a net loss of $21.4 million, while successfully remediating a material weakness in internal controls and settling a securities class action.

CareDx achieved profitability in 2024, driven by revenue growth and strategic initiatives, while addressing regulatory challenges and focusing on operational excellence.

CareDx, Inc.'s recent SEC filing details its capital stock structure, voting rights, and measures designed to deter hostile takeovers.

Jeffrey Adam Novack, Secretary and General Counsel of CareDx, Inc., reported a transaction in 2,872 shares of common stock on August 1, 2026.

John Walter Hanna Jr, President and CEO and a Director of CareDx, Inc., sold 118,000 shares of common stock on July 16, 2026.

Hannah Valantine, a Director of CareDx, Inc., sold 28,779 shares of common stock on July 16, 2026.

Michael Goldberg, a Director at CareDx, Inc., received a grant of 1,746 shares of common stock as part of his non-employee director compensation.

CareDx Chief Commercial Officer Jessica Meng reported a transaction involving company common stock, including shares withheld for tax obligations and shares acquired through an employee stock purchase plan.

CareDx CFO & COO Keith Kennedy reports a transaction involving common stock, including shares withheld for tax obligations and shares acquired through an employee stock purchase plan.

CareDx, Inc. announced its 2026 Annual Meeting of Stockholders, scheduled for June 11, 2026, to elect directors, ratify auditor appointment, and approve an amendment to increase shares available under its 2024 Equity Incentive Plan.

CareDx, Inc. has filed definitive additional materials related to its proxy statement with the Securities and Exchange Commission.

CareDx is asking stockholders to approve an amendment to its 2024 Equity Incentive Plan to increase the share reserve by 1,600,000 shares.

CareDx, Inc. has filed definitive additional materials related to its proxy statement with the Securities and Exchange Commission.

CareDx has scheduled its annual stockholders meeting for June 13, 2024, to vote on director elections, auditor ratification, executive compensation, and a new equity incentive plan.

Baron Capital Group, along with its affiliates, has reported an amendment to its Schedule 13G filing, indicating a change in its beneficial ownership of CareDx, Inc. common stock.

Gagnon Securities LLC, Gagnon Advisors, LLC, and Neil Gagnon have updated their beneficial ownership filings for CareDx, Inc., reporting a combined stake.

State Street Corporation has disclosed beneficial ownership of 4.8% of CareDx Inc.'s common stock as of June 30, 2026.

The Vanguard Group reported a 0% beneficial ownership in CareDx Inc. following an internal realignment that disaggregates its reporting.

Neil Gagnon and affiliated entities, Gagnon Securities LLC and Gagnon Advisors, LLC, report a combined beneficial ownership of 5.9% in CareDx, Inc. common stock.

State Street Corporation has reported a 5.3% beneficial ownership stake in CareDx Inc., holding over 2.7 million shares.